The COVID-19 epidemic is a historic public health concern that has had a substantial influence on the global market for hyperhidrosis treatment. At the moment, countries throughout the world are struggling to obtain some medications because to shutdown limitations and the advent of new COVID-19 variations. According to a January 2021 published study titled “Paroxysmal hypothermia and hyperhidrosis with aggravation following COVID-19 infection,” hypothermia alternated with fever for four days during the acute phase of the COVID-19 infection. Additionally, the same source claims that following the recovery phase, episodic hyperhidrosis and hypothermia remained in the absence of fever despite the use of clonidine.
As a result, hyperhidrosis treatment Market demand has skyrocketed. However, because the pandemic is still in its early stages, market participants are seeing a major impact from the COVID-19. According to the International Hyperhidrosis Society, perspiration “may really aid in the prevention of Covid-19 transmission.” The organization cites professionals such as dermatologist Adam Friedman of George Washington University, who adds that “sweat has some natural antibacterial action.” COVID-19’s immediate and direct potential impact, on the other hand, has already resulted in the death of millions of people and a significant increase in healthcare costs.
Read Report: https://www.zionmarketresearch.com/report/hyperhidrosis-treatment-market
The primary reasons driving the hyperhidrosis treatment market expansion are the increasing prevalence of secondary hyperhidrosis and the increased expenditure in research & development by industry participants.
Additionally, the promising pipeline for hyperhidrosis treatment, the rising prevalence of depression and anxiety, the growing awareness of hyperhidrosis, and the presence of advantageous reimbursement policies could all effect market growth. For example, the International Hyperhidrosis Society offers helpful resources, information, and downloadable documents pertaining to the insurance and reimbursement processes. Due to the aforementioned causes, several global market players are active in the manufacture and distribution of hyperhidrosis treatment solutions.
Additionally, these market participants employ both inorganic and organic methods, such as expansions, product launches, acquisitions, collaborations, mergers, and partnerships, to develop a strong presence and broaden their geographic reach. For example, in April 2021, Fortress Biotech and its partner business Journey Medical signed a definitive deal to buy Qbrexza (glycopyrronium) in the United States of America from Dermira, an Eli Lilly wholly-owned subsidiary. As a result of these reasons, the studied market is predicted to expand. However, the short-term results of aesthetic and therapeutic operations are a significant issue impeding the hyperhidrosis treatment market’s growth.
The Report’s Scope
According to the report’s definition, hyperhidrosis is a condition in which a patient experiences excessive sweating that is unrelated to environmental factors or thermoregulatory requirements. The Hyperhidrosis Treatment Market is split by Disease Type (Primary Focal Hyperhidrosis, Secondary Generalized Hyperhidrosis), Treatment Type (Topical, Disposable, Surgical, Botulinum Toxin A, Iontophoresis, Laser Treatments, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). Additionally, the market study includes estimated market estimates and trends for 17 countries across major worldwide regions. The report provides dollar values for the aforementioned segments.
Botulin Toxin A is Expected to Dominate the Hyperhidrosis Treatment Market
Botulinum toxin type A is a noninvasive, safe, and effective treatment for localized hyperhidrosis that lasts longer than topical therapies. Botulinum toxin injections are most frequently used to treat axillary hyperhidrosis, but they are also effective for palmar and plantar illness. Botulinum toxin’s effects typically last six to nine months, and treatment is associated with a high proportion of patient satisfaction.
The US Food and Drug Administration (FDA) approved BOTOX (onabotulinumtoxinA) in 2004 for the treatment of severe primary axillary hyperhidrosis (excessive sweating of the underarms) in individuals who were unable to find relief with antiperspirants. AbbVie, Inc. owns BOTOX, the world’s most extensively investigated botulinum toxin. BOTOX has been licensed in at least 20 countries for the treatment of excessive underarm perspiration. It may also be used “off-label” to treat facial, foot, and hand sweating.
OnabotulinumtoxinA can be used to treat excessive sweating in the armpits, hands, feet, head and face (craniofacial), and other relatively tiny body locations (such as under the breasts), according to a paper published in the International Hyperhidrosis Society in 2020. When used to treat excessive sweating beneath the arms, Botox has been proven to reduce perspiration by 82–87 percent. The effects begin to manifest two to four days following treatment, with the full extent of the effects typically manifesting within two weeks. Dryness typically lasts between four and twelve months, however some studies have discovered that it can last up to fourteen months.
Additionally, multiple research have established its efficiency in alleviating anxiety. For instance, a study published in the journal Scientific Reports in 2021 found that participants who had Botox injections at four different spots reported experiencing anxiety substantially less frequently than those who received various treatments for the same illnesses. Botox patients’ risk of anxiety was found to be reduced by 22% to 72%